Supplements · Metabolic & Cardiometabolic
coenzyme Q10 mitigates statin-associated muscle symptoms
In plain terms: Does CoQ10 relieve statin-related muscle pain?
Part of: 🧪 coenzyme Q10
Genuinely uncertain—meta-analyses split down the middle, and much statin muscle pain is a nocebo effect, so don't count on it.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
CoQ10 for statin-associated muscle symptoms is genuinely contested — meta-analyses split. A 2025 MA (7 RCTs, n=389) found a significant pain reduction (WMD −0.96), but an earlier 2020 MA found no significant improvement in myalgia or statin adherence.
The evidence (13)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Kovacic et al. 2025 · J Nutr Sci | meta-analysis | supports | low | MA of 7 RCTs (n=389, 100-600 mg/d, 30-90 d): significant SAMS pain reduction WMD -0.96 (95% CI -1.88,-0.03); significant in 4/7 trials, null in 3. |
| Derosa et al. 2019 · Drug Des Devel Ther | RCT | supports | moderate | Double-blind RCT (dyslipidemic, statin symptoms): CoQ10 liquid reduced statin-related clinical symptoms vs placebo. |
| Kumble J et al 2026 · study_type: observational | observational | mixed | low | Narrative review noting CoQ10 studies for statin myopathy 'have yielded inconsistent results, with some reporting symptom relief and others showing no significant benefit'; no routine supplementation currently recommended. |
| Valenti F et al 2025 · study_type: in-vitro | in-vitro | supports | low | In human dermal fibroblasts, atorvastatin caused oxidative stress/mitochondrial impairment; CoQ10 co-supplementation significantly reduced ROS and restored mitochondrial oxygen consumption and ATP/ADP ratio. |
| Zeeshan M et al 2025 · study_type: observational | observational | supports | low | Observational study, n=106 SAMS patients (CoQ10 50mg BID, n=53 vs no supplementation, n=53); CoQ10 group showed significantly greater reduction in VAS and pain-interference scores vs comparator (p=0.001). |
| Ahmad K et al 2024 · study_type: meta-analysis | observational | supports | low | Systematic review (PRISMA) of 1 meta-analysis + 4 RCTs, n=800 total, oral CoQ10 vs placebo in statin-associated myalgia; all 4 RCTs showed improvement in SAMS with CoQ10 supplementation, no notable side effects. |
| Taylor et al. 2015 · Atherosclerosis | RCT | contradicts | moderate | RCT in confirmed statin myopathy: CoQ10 did NOT reduce muscle pain vs placebo. ↩ SUPERSEDED — pooled in the review above, counted once |
| Fedacko et al. 2013 · Can J Physiol Pharmacol | RCT | supports | low | Double-blind pilot (n=60): CoQ10 cut SAM muscle pain ~53%, plus weakness/cramps/fatigue vs placebo (selenium no added effect). ↩ SUPERSEDED — pooled in the review above, counted once |
| Csengo E et al 2024 · study_type: observational | observational | contradicts | low | n=67 statin-naive STEMI patients; statin therapy reduced plasma CoQ10 by 43% and reduced (not increased) the myopathy marker FABP3 by 79%, with no correlation between CoQ10 change and FABP3 change. |
| Kennedy et al. 2020 · Atherosclerosis | meta-analysis | contradicts | moderate | MA: CoQ10 did not significantly improve statin-associated myalgia or maintain statin adherence vs placebo. |
| Ganamurali N et al 2026 · study_type: mechanism | mechanism | supports | low | In-silico network-pharmacology analysis mapping statin-induced CoQ10 depletion to TNF-MAPK-driven mitochondrial/muscle injury; proposes CoQ10 supplementation as a rationally-derived mechanistic strategy, not tested clinically. |
| Young et al. 2007 · Am J Cardiol | RCT | contradicts | moderate | RCT (n=44, prior simvastatin myalgia): CoQ10 200 mg did NOT improve myalgia score or statin tolerance vs placebo. |
| d10-32581-jkifm-2026-9-1-63 2026 · Korean Institute for Functional Medicine | observational | mixed | low | Functional-medicine narrative review of SAMS management proposing CoQ10 (alongside vitamin D, magnesium, L-carnitine) as part of a nutritional strategy; no dedicated trial data on CoQ10 alone extracted. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.